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1LETTER TO THE EDITOR
o Influence of V617F Mutation in JAK2 on Outcome
fter Allogeneic Hematopoietic Stem Cell
ransplantation (HSCT) for Myelofibrosis
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4The occurrence of an acquired single-point muta-
ion (Val617Phe) of the tyrosine kinase gene JAK2 in
large proportion of patients with polycythemia vera,
ssential thrombocythemia, and myeloﬁbrosis with
yeloid metaplasia has been recently published [1-5].
ampbell et al [6] recently reported poorer survival in
atients with idiopathic myeloﬁbrosis positive for
617F mutation [6]. Their study prompted us to eval-
ate the frequency of this speciﬁc JAK2 gene mutation
n patients with myeloﬁbrosis before a scheduled my-
loablative allogeneic transplantation to correlate pre-
ransplantation JAK2 V617F mutation status with
ost-transplantation outcome. If the V617F mutation
tatus in JAK2 determines the survival in the conven-
ional course of idiopathic myeloﬁbrosis, the presence
f a JAK2 gene mutation may also have implications
n the post-transplantation outcome of patients with
yeloﬁbrosis with myeloid metaplasia undergoing al-
ogeneic hematopoietic stem cell transplantation
HSCT).
We screened 30 samples from patients with idio-
athic myeloﬁbrosis (n  19), post-polycythemic my-
loid metaplasia (n  6), and post-thrombocythemic
yeloid metaplasia (n  5) who underwent transplan-
ation at our center between 1997 and 2006 for JAK2
617 gene mutation using real-time polymerase chain
eaction. Cumulative estimates were calculated by the
aplan-Meier method and comparisons between pa-
ient groups were done by log-rank test (Mantel-
aenszel).
In total, 16 patients (53%) were found to be
617F-positive before transplantation, which is in
ccordance to previous reports on the frequency of
cquired JAK2 gene mutations in myeloproliferative
isorders [1-5]. With a median of 13 months of post-
ransplantation follow-up, 7 patients positive for
617F and 5 patients negative for V617F died. The
robability of survival after transplantation was not
igniﬁcantly different for V617F-positive (75%) ver-
us V617F-negative (71%) patients. In contrast, 14
atients classiﬁed as low risk according to clinical risk
tratiﬁcation based on the presence of adverse prog-
ostic factors before myeloablative allogeneic HSCT
3507,8] were found to have a signiﬁcantly higher prob-
bility of survival compared with 16 patients classiﬁed
s high risk (72  14% versus 20  12%, P  .03).
he frequency of relapse was not inﬂuenced by the
AK2 gene mutation. Three relapses were each iden-
iﬁed among patients positive and negative for V617F.
ll 3 JAK2-positive patients who relapsed became
ositive for V617F again after initial JAK2 negativity
fter transplantation. Within a subgroup of 19 pa-
ients with a median follow-up period of 24 months
fter transplantation, 2 patients initially positive and 2
atients primarily negative for V161F relapsed.
These preliminary observations show that, consid-
ring the outcome after allogeneic HSCT, a pre-
xistent JAK2 V617F mutation seems to have less
rognostic signiﬁcance with respect to relapse risk and
urvival than do clinically assessed features of myelo-
brosis. Although a V617F mutation in JAK2 might
lay an important role as a prognostic molecular
arker or as a potential therapeutic target in the
onventional course of idiopathic myeloﬁbrosis, its
igniﬁcance in the transplantation setting probably lies
n its use as a minimal residual disease marker. How-
ver, if the signiﬁcance of a V617F mutation as an
dverse molecular prognostic marker in idiopathic
yeloﬁbrosis is conﬁrmed in further studies, then this
ould improve the accuracy of risk stratiﬁcation and
ay support a timely assignment to allogeneic HSCT
n patients positive for V617F.
EFERENCES
. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of
the tyrosine kinase JAK2 in human myeloproliferative disorders.
Lancet. 2005;365:1054-1061.
. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2
mutation leading to constitutive signaling causes polycythaemica
vera. Nature. 2005;434:1144-1148.
. Jones AV, Kreil, S, Zoi K. Widespread occurrence of JAK2
V617F mutation in chronic myeloproliferative disorders. Blood.
2005;106:2162-2168.
. Levine RL, Wadleigh M, Cools J. Activating mutation in the
tyrosine kinase JAK2 in polycythemia vera, essential thrombo-
56
7
8
M
A
R
N
M
D
D
U
Letter to the Editor 1351cythemia, and myeloid metaplasia with myeloﬁbrosis. Cancer
Cell. 2005;7:387-397.
. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function
mutation of JAK2 in myeloproliferative disorders. N Engl J Med.
2005;352:1779-1790.
. Campbell PJ, Griesshammer M, Döhner K, et al. V617F muta-
tion in JAK2 is associated with poorer survival in idiopathic
myeloﬁbrosis. Blood. 2006;107:2098-2100.
. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell
transplantation for agnogenic myeloid metaplasia: a European
Group for Blood and Marrow Transplantation, Societe Fran-
caise de Greffe de Moelle, Gruppo Italiano per il Trapianto del
Midollo Osseo, and Fred Hutchinson Cancer Research Center
Collaborative Study. Blood. 1999;93:2831-2838. E. Ditschkowski M, Beelen DW, Trenschel R, et al. Outcome of
allogeneic stem cell transplantation in patients with myeloﬁbro-
sis. Bone Marrow Transplant. 2004;34:807-813.
arkus Ditschkowski, MD
hmet H. Elmaagacli, MD
udolf Trenschel, MD
ina K. Steckel, MD
ichael Koldehoff, MD
ietrich W. Beelen, MD
epartment of Bone Marrow Transplantation
niversity Hospital of Essen
ssen, Germany
